Thymalfasin Immunotherapy Explored for Advanced Colorectal Cancer After Standard Treatment Failure
"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"
Background
Colorectal cancer (CRC) remains a significant global health challenge, particularly in its advanced metastatic (MCRC) form. Patients with Microsatellite Stable (MSS) or Proficient Mismatch Repair (pMMR) tumors often respond poorly to conventional immunotherapies, especially after failing initial standard-of-care treatments. This study addresses the critical need for improved therapeutic strategies for advanced MSS/pMMR MCRC patients with limited options.